Big picture view: Retatrutide is the next step in the class of drugs known as GLP-1s
GLP-1 receptor agonists should be considered when patients experience significant weight regain with BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m, lifestyle modifications have been insufficient, no anatomical complications require surgical revision, and patients are willing to engage in long-term pharmacotherapy
Start meeting biweekly with a health coach for accountability and support
These findings shifted medical understanding, prompting weight loss specialists and bariatricians to incorporate semaglutide into treatment protocols despite the lack of formal FDA weight-loss indication
For this reason,, pulse rate should be monitored routinely in patients taking semaglutide, and the medication should be stopped in those with sustained increases [99]
Structure, catalytic mechanism, and evolution of the glutathione transferases